GlassScriptPhysician profile
Jose Mandujano
NPI 1508817206
$10,419.32
in general payments reported to CMS, 2019-2025
35 companies · $1,323 in 2025
The $1,323 reported for 2025 was more than what 90% of Pediatric Pulmonology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,246 · 2020: $1,097 · 2021: $1,827 · 2022: $1,994 · 2023: $1,297 · 2024: $1,636 · 2025: $1,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,222 · Education: $34.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,222.12 |
| Education | $34.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,791.35 | 2019-2025 | Fasenra, Tezspire, Flumist Quadrivalent |
| Regeneron Healthcare Solutions, INC. | $725.15 | 2020-2024 | Dupixent |
| Genzyme Corporation | $659.24 | 2019-2025 | |
| Glaxosmithkline, LLC. | $653.91 | 2019-2025 | Nucala |
| Vertex Pharmaceuticals Incorporated | $638.74 | 2019-2025 | Trikafta |
| Grifols USA, LLC | $609.49 | 2021-2025 | Xembify, Gamunex-C |
| Abbvie INC. | $570.40 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $561.87 | 2020-2025 | Hyqvia, Cuvitru |
| Covis Pharma Gmbh | $490.44 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $442.69 | 2019-2024 | |
| Csl Behring | $425.94 | 2019-2025 | Hizentra, Privigen |
| Genentech USA, INC. | $325.65 | 2020-2025 | Xolair |
| Amgen INC. | $324.60 | 2021-2025 | Tezspire |
| Baxter Healthcare | $286.09 | 2022-2025 | Hillrom - Vest System Model 105 Home Care |
| Philips North America LLC | $213.93 | 2019-2025 | (Ak6) Vest Therapy, Vest Therapy Und |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $207.72 | 2019-2022 | |
| Chiesi USA, INC. | $177.37 | 2021-2022 | |
| Advanced Respiratory, INC | $157.88 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $154.34 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $130.89 | 2021-2023 | |
| Ars Pharmaceuticals Operations, INC. | $109.53 | 2025 | Neffy |
| Nestle Healthcare Nutrition INC. | $104.28 | 2020-2023 | |
| Allergan, INC. | $95.10 | 2019 | |
| Pharming Healthcare, INC. | $91.90 | 2024-2025 | Ruconest |
| Horizon Therapeutics Plc | $79.71 | 2022-2023 | Actimmune |
| Electromed, INC. | $74.33 | 2022-2024 | Smartvest |
| Octapharma USA, INC. | $59.30 | 2023-2024 | Octagam Immune Globulin (Human), Panzyga |
| Mylan Specialty L.P. | $51.62 | 2020-2021 | |
| Shire North American Group INC | $50.37 | 2019 | |
| Gilead Sciences, INC. | $47.67 | 2020-2022 | |
| Pfizer INC. | $26.27 | 2021 | |
| Aytu Biopharma, INC. | $25.44 | 2020-2021 | |
| Alk-Abello, INC | $20.65 | 2022 | |
| Kaleo, INC. | $20.27 | 2023 | Auvi-Q |
| Vivus LLC | $15.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Mandujano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.